A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis

Ruzicka, Thomas; Bieber, Thomas; Schöpf, Erwin; Рубинс, Андрис; Bos, Jan D.; Jabłońska, Stefania; Ahmed, I.; Thestrup‐Pedersen, Kristian; Dániel, F; Finzi, A. F.; Reitamo, Sakari

doi:10.1056/nejm199709183371203

Cited by 493 publications

(189 citation statements)

References 17 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…Topical application of cyclosporine is not effective, 13 in contrast to the cyclic macrolide tacrolimus (FK 506), which proved to be effective in treating patients with AD. 14,15 Results of studies of the topical treatment of allergic contact dermatitis in pigs with other cytokine-inhibiting, antiinflammatory drugs, such as the ascomycin derivative (SDZ ASM 981), indicated that they might be effective in the topical treatment of skin disease in man. 16,17 Clearing of psoriatic lesions has been reported after topical application of 1% SDZ ASM 981 ointment under occlusion for 14 days (U.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis

Leent

Graber²,

Thurston³

et al. 1998

Arch Dermatol

Self Cite

203

106

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis

Leent

Graber²,

Thurston³

et al. 1998

Arch Dermatol

Self Cite

203

106

View full text Add to dashboard Cite

“…For topical uses of tacrolimus that do not increase systemic blood concentration of the content, systemic tacrolimus levels were negligible when compared with using systemic agents (24,25). Therefore, it is suggested that unknown systemic factors may play a critical role in the local skin healing process, such as diabetes mellitus.…”

Section: Discussionmentioning

confidence: 99%

Topical tacrolimus does not negatively impact acute skin wound healing

Namkoong

Chung

Yoo

et al. 2013

Experimental Dermatology

View full text Add to dashboard Cite

Despite the increasing use of topical tacrolimus, there is little information about its effect on skin wound healing. To determine effects on acute cutaneous wound healing, two fullthickness skin wounds were imparted on the backs of 45 hairless mice, which were then divided into vehicle-, topical tacrolimusand topical steroid-treated group. Each drug was topically applied once daily. The wound area was assessed by using dermoscopic images every two days after wounding. At 3, 7 and 11 days after wounding, 10 wounds in each group were collected for semiquantitative analysis of histological features including re-epithelialization, polymorphonuclear leucocytes, fibroblasts and collagen. We also checked the mRNA expression levels of EGF, TGF-b, TNF-a and IL-1a. While topical application of clobetasol propionate was found to delay re-epithelialization and infiltration of polymorphonuclear leucocyte, topical treatment with tacrolimus showed patterns similar to that of the vehicle. In the tacrolimus-treated group, mRNA expression levels of IL-1a and TGF-b were slightly decreased, while the others were similar with the vehicle-treated group. Unlike steroid, topical tacrolimus, therefore, did not disturb the wound healing process in a murine skin wound model.

show abstract

“…23) Clinical trials have shown that short-term administration of topical tacrolimus is extremely effective and safe for controlling pruritus and skin inflammation. 11,12) In the mouse dermatitis model induced by repeated 2,4-dinitrofluorobenzene (DNFB) painting, tacrolimus significantly inhibited the scratching behavior, whereas dexamethasone had no effect. Tacrolimus possesses an anti-scratching activity that is not common in glucocorticoids.…”

Section: Discussionmentioning

confidence: 99%

“…In two studies, reduction of pruritus was significantly higher for tacrolimus-treated patients than for vehicle-treated patients. 11,12) Therefore, we examined whether tacrolimus could produce an anti-pruritic effect in this model.…”

mentioning

confidence: 99%

Participation of Proteinase-Activated Receptor-2 in Passive Cutaneous Anaphylaxis-Induced Scratching Behavior and the Inhibitory Effect of Tacrolimus

Zhu

Pan

et al. 2009

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Proteinase-activated receptor-2 (PAR2) may be an important regulator of skin mast cell function during cutaneous inflammation and hypersensitivity. However, little is known of the role of PAR2 in allergic pruritus, because mast cells, which are thought to be responsible for this symptom, can release a number of different pruritogens. In the present study, we investigated the effects of several agents on passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. As a result, cetirizine and ketanserin produced dose-dependent inhibition of scratching behavior induced by passive cutaneous anaphylaxis. Combined cetirizine with ketanserin exhibited significant inhibitory effects for the number of passive cutaneous anaphylaxis-induced scratching behavior. Pretreatment of the experimental animals with PAR2-neutralizing antibody and protease inhibitor leupeptin significantly inhibited passive cutaneous anaphylaxis-induced scratching behavior. Furthermore, we found that topical application of tacrolimus significantly reduced the number of scratching behavior induced by passive cutaneous anaphylaxis in a dose-dependent manner. Combined cetirizine with tacrolimus also exhibited significant inhibitory effects for the number of passive cutaneous anaphylaxis-induced scratching behavior. Tacrolimus in doses of 3% and 10% significantly inhibited tryptase-induced scratching behavior. These results suggest that PAR2 may be involved in passive cutaneous anaphylaxis-induced scratching behavior and tacrolimus produces an anti-allergic pruritus effect in ICR mice.

show abstract

A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis

Abstract: A short-term trial of tacrolimus ointment for atopic dermatitis Ruzicka, T.; Bieber, T.; Schopf, E.; Rubins, A.; Dobozy, A.; Bos, J.D.; Jablonska, S.; Ahmed, I.; Thestrup-Pedersen, K.; Daniel, F.; Finzi, A.; Reitamo, S.

Cited by 493 publications

References 17 publications

Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis

Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis

Topical tacrolimus does not negatively impact acute skin wound healing

Participation of Proteinase-Activated Receptor-2 in Passive Cutaneous Anaphylaxis-Induced Scratching Behavior and the Inhibitory Effect of Tacrolimus

Contact Info

Product

Resources

About